// Company Overview //
| Stock Name | 雅各臣科研製藥有限公司 |
| Stock Code | 02633 |
| Company Full Name | 雅各臣科研製藥有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在香港從事開發、制造及分銷非專利藥物、品牌藥、品牌中藥及健康保健品。 |
| Listing Date | 2016-09-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍觀塘道388號創紀之城1期1座23樓2313-18室 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.jacobsonpharma.com |
| Share Registrar | 卓佳證券登記有限公司 |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2016-09-08 |
| Offer Price | HK$ 1.50 / shares |
| Total Funds Raised | HK$ 65,628,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
// First Day Performance
| First Day Close | Loading... |
| First Day Open | HK$ 1.58 |
| First Day Change | 12.00% |
| First Day Volume | 107290000.0 |
| First Day Turnover | 173359000.0 |
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、約45%(或270.5百萬港元)用作收購事項;
2、約18%(或108.2百萬港元)用作有關收購、拓展、精簡或提升我們的制造廠房、房產、設施或產能的資本投資;
3、約15%(或90.2百萬港元)用作為專門非專利藥進行生物等效性臨床研究;
4、約12%(或72.1百萬港元)用作在未來五年加大我們的銷售、市場推廣及廣告宣傳力度,以提升品牌的認可度及加強我們產品及業務的品牌忠誠度;
5、約10%(或60.1百萬港元)用作營運資金及其他一般公司用途。 |
// Underwriting Syndicate //
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
| 1 |
New Heritage Healthcare Limited |
49,998,000 HKD |
— |
1.90% |
— |
6 months |
2017-03-21 |
| 2 |
香港荣华药业集团有限公司 |
79,998,000 HKD |
— |
3.00% |
— |
6 months |
2017-03-21 |
// Directors & Management //
| Chairman | 岑廣業 |
| Company Secretary | 余振球 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 岑廣業(60.59%);云南白藥控股有限公司(10.34%);劉榮雄及家族成員(8.11%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.